KR20160130780A - Methods for diagnosing and treating inflammatory
4.5 (413) · € 15.50 · Auf Lager
Official gazette of the unexamined patents
Long non-coding RNA CDKN2B-AS1 reduces inflammatory response and promotes cholesterol efflux in atherosclerosis by inhibiting ADAM10 expression
The Clinical Response of Upadacitinib and Risankizumab is Associated with Reduced Inflammatory Bowel Disease Anti-TNFα Inadequate Response Mechanisms
Rheumatoid Arthritis Basics: Diagnosis, Treatment, and Steps to Take
사카로미세스 세레비시아 그램 염색
EP3095444A1 - A method of treating peripheral inflammatory disease - Google Patents
Co-Expression Analysis, PDL1 Expression
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial - The Lancet Gastroenterology & Hepatology
Frontiers Mass cytometry and single-cell RNA sequencing reveal immune cell characteristics of active and inactive phases of Crohn's disease
Serum Inflammatory Mediators as Markers of Human Lyme Disease Activity
Inflammatory bowel disease biomarkers - Liu - 2022 - Medicinal Research Reviews - Wiley Online Library
Serum Inflammatory Mediators as Markers of Human Lyme Disease Activity
KR20160130780A - Methods for diagnosing and treating inflammatory bowel disease - Google Patents
Inflammation and tumor progression: signaling pathways and targeted intervention
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19 - ScienceDirect
Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy
